DiaSorin S.p.A. (DSRLF) Reports Successful Double-Digit Growth in Immunodiagnostic and Molecular-Based Businesses in 2023

March 16, 2024 | by


DiaSorin S.p.A. (DSRLF), a leading global diagnostic company, reported impressive double-digit growth in its immunodiagnostic and molecular-based businesses for the year 2023. During their Q4 2023 earnings conference call held on March 15, 2024, DiaSorin announced the successful achievement of their strategic goals in the challenging Chinese market, solidifying their local leadership and gaining approval for their LIAISON reagents. The company experienced significant growth in their CLIA business, particularly in the US and Europe, despite the obstacles faced in China. However, the COVID business declined by 75% in 2023, and while it is expected to continue declining in 2024, the molecular diagnostic business, excluding respiratory and COVID, displayed a promising 6% growth rate with double-digit growth in the fourth quarter. Contributing to this growth were the advances in VERIGENE 1 technology and low plex offerings. Although the molecular respiratory business experienced a decline in Q4 due to seasonal factors, DiaSorin remains confident in the appeal of their LIAISON PLEX automation, anticipating it to be an attractive choice for customers. Overall, with the achievement of their milestones, DiaSorin looks forward to a future of stabilization and growth.

95paON4hdScokCN81ZxAmvSwy3KpQiLRNGBF4qemM 복사본

Double-Digit Growth in Immunodiagnostic and Molecular-Based Businesses

DiaSorin S.p.A. (DSRLF) had a successful year in 2023, with double-digit growth in both its immunodiagnostic and molecular-based businesses. This achievement is a testament to the company’s commitment to innovation and its ability to meet the evolving needs of the healthcare industry.

CLIA Business Growth

DiaSorin experienced double-digit growth across all geographies in its CLIA business. Particularly, the company saw strong growth in the United States and Europe. This growth can be attributed to the increasing demand for accurate and reliable diagnostic solutions in these regions.

Screenshot 2024 01 08 192459 1

Strategic Goals in the Chinese Market

Despite facing challenges, DiaSorin achieved its strategic goals in the Chinese market. One of the key accomplishments was attaining local leadership. This achievement showcases the company’s understanding of the Chinese market and its ability to effectively navigate the complexities of doing business in the region.

Additionally, DiaSorin successfully commenced the manufacturing of LIAISON reagents in China. This localization of production not only strengthens the company’s presence in the Chinese market but also allows for better responsiveness to the needs of local customers.

Furthermore, DiaSorin obtained VBP (Value-Based Procurement) approval for its products in China. This approval is an important recognition of the quality and value of DiaSorin’s offerings, solidifying the company’s position in the Chinese market.

However, it is important to acknowledge that DiaSorin faced challenges in China, as is often the case when entering new markets. These challenges may include regulatory hurdles, competition from local players, and cultural differences. Nevertheless, DiaSorin’s ability to overcome these challenges and achieve its strategic goals in China is commendable.

Decline in COVID Business

In 2023, DiaSorin experienced a significant decline of 75% in its COVID business. This decline can be attributed to several factors, such as the increasing availability of vaccines, the easing of restrictions, and the overall declining prevalence of COVID-19 cases.

Unfortunately, this decline is expected to continue in 2024. As the global population becomes more vaccinated and the pandemic is brought under control, the demand for COVID-related diagnostic solutions is anticipated to decrease. However, DiaSorin remains resilient and continues to adapt its business strategies to align with the changing landscape.


Growth in Molecular Diagnostic Business

Excluding respiratory and COVID-related diagnostics, DiaSorin’s molecular diagnostic business experienced a 6% growth in 2023. This growth is a notable achievement and reflects the company’s ability to provide innovative and reliable solutions beyond the scope of COVID testing.

In the fourth quarter, DiaSorin saw double-digit growth in its molecular diagnostic business. This accelerated growth can be attributed to the successful introduction of the VERIGENE 1 technology and the offering of low plex solutions. These advancements have expanded DiaSorin’s product portfolio and allowed the company to cater to a wider range of diagnostic needs.

Decline in Molecular Respiratory Business

Despite the overall growth in the molecular diagnostic business, DiaSorin experienced a significant decline in its molecular respiratory business in the fourth quarter. This decline can be attributed to the seasonality of the flu season, which often leads to a decrease in respiratory-related diagnostic testing.

Seasonal fluctuations are a common occurrence in the healthcare industry, and DiaSorin is well aware of the impact they can have on specific segments of its business. The company remains adaptable and continues to invest in research and development to mitigate the effects of these seasonal fluctuations.

Attractiveness of LIAISON PLEX Automation

DiaSorin is confident in the attractiveness of its LIAISON PLEX automation. The company believes that this automated system will be a compelling proposition for its customers. The LIAISON PLEX automation streamlines and simplifies the diagnostic process, enhancing efficiency and accuracy.

With the increasing demand for diagnostic testing, automation becomes crucial in optimizing workflow and reducing human error. DiaSorin’s LIAISON PLEX automation offers a comprehensive solution that addresses these needs, and the company expects it to be well-received by customers.

Achievement of Milestones and Expectations

Overall, DiaSorin achieved its milestones in 2023 and remains optimistic about future growth. The company’s ability to achieve double-digit growth in its immunodiagnostic and molecular-based businesses, despite challenges in certain segments, demonstrates its resilience and commitment to innovation.

Looking ahead, DiaSorin expects stabilization and growth in the coming year. The company’s understanding of market dynamics, strategic goals in key markets, and the development of innovative technologies position DiaSorin for continued success in the rapidly evolving field of diagnostic testing. Through its dedication to improving patient outcomes and meeting customer needs, DiaSorin is poised to make a significant impact in the healthcare industry.

420975661 930960805057803 3457597750388070468 n


View all

view all